Abstract Tamoxifen (ICI 46 474), trans-1-(4-β-dimethylaminoethoxyphenyl)-1, 2-diphenylbut-
1-ene, is the most commonly used drug for the treatment of estrogen receptor positive breast …

Postmenopausal women are at high risk of developing breast cancer due to estrogen
production in peripheral tissues of the body other than ovaries. Aromatase is present in …

Drug resistance is a major challenge in conventional endocrine therapy for estrogen
receptor (ER) positive breast cancer (BC). BC is a multifactorial disease, in which …

Endocrine therapy is currently the main therapeutic approach for estrogen receptor-positive
(ER+) breast cancer, the most frequent subtype of breast cancer in women worldwide. For …

Breast cancer, emerging malignancy is common among women due to overexpression of
estrogen. Estrogens are biosynthesized from androgens by aromatase, a cytochrome P450 …

Background: Breast cancer is considered to be 2nd most common cancer subtype
investigated worldwide. It is mainly prevalent in postmenopausal women. Estrogen Receptor …

Aromatase is an enzyme that plays a crucial role in the biosynthesis of estrogens, which are
hormones that contribute to the growth of certain types of breast cancer. In particular …

Breast cancer is a major threat to women's lives throughout the world. Hormone-dependent
or estrogen-receptor positive (ER+) breast cancer accounts for more than 80% of all …

Breast Cancer (BC) is a leading cause of death in women, currently affecting 13% of female
population worldwide. First-line clinical treatments against Estrogen Receptor positive (ER+) …

Around 70–85% of all breast cancer (BC) cases are estrogen receptor-positive (ER+). The
third generation of aromatase inhibitors (AIs) is the first-line treatment option for these …